GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Abbott Laboratories (NYSE:ABT) » Definitions » Piotroski F-Score

Abbott Laboratories (Abbott Laboratories) Piotroski F-Score

: 6 (As of Today)
View and export this data going back to 1949. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Abbott Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Abbott Laboratories's Piotroski F-Score or its related term are showing as below:

ABT' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Abbott Laboratories was 9. The lowest was 5. And the median was 6.


Abbott Laboratories Piotroski F-Score Historical Data

The historical data trend for Abbott Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbott Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 9.00 5.00 6.00

Abbott Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 6.00 -

Competitive Comparison

For the Medical Devices subindustry, Abbott Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 1318 + 1375 + 1436 + 1594 = $5,723 Mil.
Cash Flow from Operations was 1143 + 1203 + 1877 + 3038 = $7,261 Mil.
Revenue was 9747 + 9978 + 10143 + 10241 = $40,109 Mil.
Gross Profit was 5416 + 5495 + 5538 + 5685 = $22,134 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(74438 + 73794 + 73354 + 72090 + 73214) / 5 = $73378 Mil.
Total Assets at the begining of this year (Dec22) was $74,438 Mil.
Long-Term Debt & Capital Lease Obligation was $14,548 Mil.
Total Current Assets was $22,670 Mil.
Total Current Liabilities was $13,841 Mil.
Net Income was 2447 + 2018 + 1435 + 1033 = $6,933 Mil.

Revenue was 11895 + 11257 + 10410 + 10091 = $43,653 Mil.
Gross Profit was 6908 + 6324 + 5781 + 5498 = $24,511 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(75196 + 74007 + 74202 + 72801 + 74438) / 5 = $74128.8 Mil.
Total Assets at the begining of last year (Dec21) was $75,196 Mil.
Long-Term Debt & Capital Lease Obligation was $15,465 Mil.
Total Current Assets was $25,224 Mil.
Total Current Liabilities was $15,489 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Abbott Laboratories's current Net Income (TTM) was 5,723. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Abbott Laboratories's current Cash Flow from Operations (TTM) was 7,261. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=5723/74438
=0.07688277

ROA (Last Year)=Net Income/Total Assets (Dec21)
=6933/75196
=0.09219905

Abbott Laboratories's return on assets of this year was 0.07688277. Abbott Laboratories's return on assets of last year was 0.09219905. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Abbott Laboratories's current Net Income (TTM) was 5,723. Abbott Laboratories's current Cash Flow from Operations (TTM) was 7,261. ==> 7,261 > 5,723 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=14548/73378
=0.19826106

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=15465/74128.8
=0.20862337

Abbott Laboratories's gearing of this year was 0.19826106. Abbott Laboratories's gearing of last year was 0.20862337. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=22670/13841
=1.63788744

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=25224/15489
=1.62851056

Abbott Laboratories's current ratio of this year was 1.63788744. Abbott Laboratories's current ratio of last year was 1.62851056. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Abbott Laboratories's number of shares in issue this year was 1745.778. Abbott Laboratories's number of shares in issue last year was 1752.459. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=22134/40109
=0.55184622

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=24511/43653
=0.56149635

Abbott Laboratories's gross margin of this year was 0.55184622. Abbott Laboratories's gross margin of last year was 0.56149635. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=40109/74438
=0.53882426

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=43653/75196
=0.5805229

Abbott Laboratories's asset turnover of this year was 0.53882426. Abbott Laboratories's asset turnover of last year was 0.5805229. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Abbott Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Abbott Laboratories  (NYSE:ABT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Abbott Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Abbott Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbott Laboratories (Abbott Laboratories) Business Description

Address
100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Executives
Andrea F Wainer officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Mccoy John A. Jr. officer: VICE PRESIDENT C/O ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael F Roman director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST. PAUL MN 55144-1000
Patricia Paola Gonzalez director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Louis H. Morrone officer: EXECUTIVE VICE PRESIDENT 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Philip P Boudreau officer: Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Michael O'grady director 50 S LASALLE STREET, CHICAGO IL 60603
Gregory A Ahlberg officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Randel William Woodgrift officer: Senior Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
John F Ginascol officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Salvadori Daniel Gesua Sive officer: Senior Vice President 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064-6092
Mary K Moreland officer: Executive Vice President 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064
Lisa D Earnhardt officer: Executive Vice President 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Robert E Funck officer: Vice President, Controller 100 ABBOTT PARK ROAD, D-378, AP6D-2, ABBOTT PARK IL 60064-6092

Abbott Laboratories (Abbott Laboratories) Headlines

From GuruFocus

Q2 2023 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2023 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2021 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2019 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2020 Abbott Laboratories Earnings Call Transcript

By GuruFocus Research 01-22-2024